Spis treści:
Spis załączników:
SFA_2023_dividend_payment_EN.pdf (REPORT)
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
SFA_2023_dividend_payment_EN.pdf (REPORT)
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 79 | / | 2024 | ||||||||
| Date of issue: | 2024-08-19 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification of commencement of dividend payment for the year 2023 | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, August 19, 2024 – In accordance with the requirements of art. 100 of LPOS “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 26, 2024 the Company will initiate the payment of the 2023 dividend of 0,09 stotinki voted on the Annual General Meeting of Shareholders held on June 28, 2024. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_2023_dividend_payment_EN.pdfSFA_2023_dividend_payment_EN.pdf | Notification of commencement of dividend payment for the year 2023 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2024-08-19 | Ognian Donev | Executive director | |||
Źródło:Komunikaty spółek (ESPI)
